Update shared on 08 Oct 2025
Fair value Increased 17%Analysts have raised their price target on Shield Therapeutics from $0.14 to $0.16 per share, citing improved profit margin expectations and a steady long-term outlook, despite minor adjustments to growth forecasts.
What's in the News
- Positive efficacy, tolerability, and palatability results for ferric maltol pediatric FORTIS clinical trial were presented at the AAP National Conference, showing significant hemoglobin improvements with no serious adverse events reported (Key Developments).
- The US FDA accepted a clinical supplement for ACCRUFeR®/FeRACCRU® and assigned Priority Review to extend its indication to adolescents aged 10 and above. Approval is anticipated in 2026, with further expansion planned for younger children (Key Developments).
- Shield Therapeutics reported positive efficacy and safety results from the ORION-HF study, demonstrating improvements in hemoglobin, exercise capacity, and quality of life for patients with heart failure and iron deficiency anemia, with publication in the European Journal of Heart Failure (Key Developments).
- £1.5 million follow-on equity offering was completed through the direct listing of 20 million new ordinary shares at £0.075 per share (Key Developments).
Valuation Changes
- Fair Value per share has increased from £0.137 to £0.16, reflecting a more favorable outlook.
- Discount Rate remains effectively unchanged at 6.82%, indicating stable risk assumptions.
- Revenue Growth projection has decreased slightly from 42.36% to 41.89%.
- Net Profit Margin is expected to improve mildly, rising from 24.44% to 24.67%.
- Future P/E ratio has climbed from 8.00x to 9.32x, which suggests the stock is now valued at a higher multiple of expected earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.